WOODCLIFF LAKE, N.J., May 22, 2024 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (the “Company” or “Eagle”) today announced...
1 day ago

Eagle Pharmaceuticals Inc., its ex-CEO, and current CFO allegedly misled investors about its revenues, failing to disclose overstatements as...
5 months ago

Eagle Pharma launches new suit over leukaemia drug.
3 months ago

Eagle Pharmaceuticals, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before February 9, 2024 to Discuss Your...
3 months ago

The restructuring will primarily affect employees involved in the commercialization of Eagle Pharmaceuticals' products Byfavo, Barhemsys, and...
2 months ago

Eagle Pharmaceuticals (EGRX) plans to cut 36% of its workforce to improve operational efficiencies and reduce sales and marketing expenses.
2 months ago

Eagle Pharmaceuticals founder Scott Tarriff has stepped down from his positions as president, CEO and board director, effective immediately.
5 months ago

Eagle Pharmaceuticals Inc (EGRX) has shared an update. Brian Cahill stepped down as CFO of Eagle Pharmaceuticals, and Steven Ratoff, a Board member,...
2 months ago

Eagle Pharmaceuticals Granted Unique J-Code and Pass-Through Status for BARHEMSYS® from CMS · BARHEMSYS causes dose- and concentration-dependent...
7 months ago

Insider Sellers Might Regret Selling Eagle Pharmaceuticals Shares at a Lower Price Than Current Market Value ... Despite the fact that Eagle...
3 months ago